STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Merkel cell carcinoma
- Focus Therapeutic Use
- Acronyms STAMP
- 12 Apr 2023 Status changed from recruiting to suspended.
- 18 Mar 2023 Planned End Date changed from 31 Oct 2023 to 31 Dec 2025.
- 18 Mar 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Dec 2025.